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doi:10.101Scoring HLA Class I Mismatches by HistoCheck Does Not
Predict Clinical Outcome in Unrelated Hematopoietic
Stem Cell Transplantation
Stephen Spellman,1 John Klein,2 Michael Haagenson,1 Medhat Askar,3
Lee Ann Baxter-Lowe,4 Jun He,5 Susan Hsu,6 Rainer Blasczyk,7 Carolyn Hurley8Currently, there is no well-accepted rating system for reliably predicting which HLA-mismatched (MM) un-
related donor should be selected for a patient without an HLA allele-matched donor.We evaluated the ability
of anMM ranking system, HistoCheck, to predict the risk associated with HLA class I disparity in a population
of 744 single allele or antigen HLA-A, -B, or -C MM myeloablative unrelated donor hematopoietic stem cell
transplantation recipients with acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelog-
enous leukemia, or myelodysplastic syndrome, facilitated through the National Marrow Donor Program be-
tween 1988 and 2003. Multivariate models were used to adjust for other significant clinical risk factors. HLA
MMs were scored using the HistoCheckWeb-based tool, and the patients were divided into 4 quartiles: dis-
similarity score (DSS) 1.04-2.84 (allele MM), DSS .2.84-13.75 (allele and antigen MM), DSS .13.75-19.39
(antigen MM), and DSS .19.39-36.62 (antigen MM). Using the lowest scoring quartile as the reference,
the DSS groups were evaluated for associations with relapse, treatment-related mortality, acute and chronic
graft-versus-host disease, leukemia-free survival, and overall survival in the entire cohort and also in subset
analyses by disease and disease stage. No significant associations were found between DSS and any outcomes
in the overall cohort using the quartile categories or treating DSS as a continuous variable. Higher DSS
scores were associated with decreased engraftment in early-stage disease (P 5 .0003), but not in other dis-
ease stages. In summary, DSS does not correlate with transplantation outcomes, and the HistoCheck scoring
system does not provide an effective technique for ranking HLA class I MM. The dataset used in this study is
available to evaluate new algorithms proposed for donor selection.
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Although HLA matching for alleles of HLA-A,
-B, -C, and -DRB1 (ie, 8/8 matches) has been shown
to optimize survival after hematopoietic stem cell
transplantation (HCT) [1,2], 30%-40% of HCTs
facilitated through the National Marrow Donor
Program (NMDP) are mismatched at 1 or more loci
[3]. Mismatching for a single allele (7/8 match) results
in a 10% reduction in average overall survival (OS)
compared with an 8/8 match; however, this risk may
be acceptable compared with that from alternative
therapies.
No rating system exists to reliably predict which
HLA-mismatched (MM) unrelated donor should be
selected for a patient who does not have an HLA
allele-matcheddonor.PreviousCenter for International
Blood and Marrow Transplant Research (CIBMTR)
studies have evaluated MM donor selection based on
serologically cross-reactive epitope groups (ie, CREGs)
[4], amino acid triplets (ie, HLA MatchMaker) [5], and739
740 Biol Blood Marrow Transplant 18:739-746, 2012S. Spellman et al.the number of amino acid differences [6,7] and found
that these selection strategies do not predict outcomes.
Although studies of donor–recipient pairs from the
Japanese Marrow Donor Program have suggested
a differential impact of specific HLA mismatches
[8-10], a recent CIBMTR report discussed the
difficulties in evaluating the impact of specific allele
mismatches in the context of mismatches at other loci
[9]. Thus, evaluating various HLA-based donor selec-
tion criteria continues to be a priority to improve the
outcomes of HCT with HLA-MM donors.
In 2002, Elsner and Blasczyk [11] suggested that
a rating system based on structural data of HLA class
I molecules might be used to identify acceptable
mismatches. Their algorithm is based on the func-
tional similarity of amino acids using a distance matrix
developed by Risler et al. [12], and on the frequency
of amino acid substitutions in proteins. Risler scores
are further weighted based on the position of the
disparity in the HLA molecule (ie, location in the pep-
tide binding or T cell receptor recognition site). In
2004, Blasczyk et al. [13] extended this algorithm to
include evaluation of class II molecules and developed
an Internet-based software tool, HistoCheck, for
assigning scores (http://www.histocheck.de/).
In 2004, Shaw et al. [14] used HistoCheck to score
26 single HLA-A allele MM recipients and 9 single
HLA-B allele MM recipients in the Anthony Nolan
clinical database. These recipients were matched for
alleles at the other key HLA loci. The investigators
compared the clinical outcomes with the HistoCheck
scores. No associations with neutrophil engraftment,
acute or chronic graft-versus-host disease (GVHD),
relapse, or survival were found in this small study. In
2011, Askar et al. [15] evaluated the correlation
between HistoCheck score and high-risk HLA allele
MM combinations previously described by Kawase
et al. [9]. They found no difference in HistoCheck
score distribution between high-risk and low-risk
allele combinations, and the HistoCheck score did
not correlate with mismatch risk stratification in the
Japanese population. We used CIBMTR data to eval-
uate the HistoCheck algorithm in a larger study to
provide guidance for HLA-MM donor selection.MATERIALS AND METHODS
Study Population
The study included patients reported to the
NMDP who underwent HCT from an unrelated
donor between 1988 and 2003. All patients and their
donors were fully HLA-typed at high resolution
through the NMDP’s ongoing retrospective high-
resolution typing project. The study included 744
donor–recipient pairs with a single HLA-A, -B or -C
mismatch. All cases were matched for HLA-DRB1and -DQB1. Eligible diagnoses included acute
lymphoblastic leukemia (ALL; n 5 199), acute mye-
logenous leukemia (AML; n5 224), chronic myeloge-
nous leukemia (CML; n 5 259), and myelodysplastic
syndrome (MDS; n 5 62). Early-stage disease was
defined as AML or ALL in first complete remission,
CML in first chronic phase, and MDS subtype refrac-
tory anemia. Intermediate-stage disease was defined as
AMLor ALL in second or subsequent complete remis-
sion or in first relapse andCML in accelerated phase or
second chronic phase. Advanced-phase disease was
defined as AML in second or subsequent relapse or
primary induction failure, CML in blast phase, MDS
subtypes refractory anemia with excess blasts or in
transformation, or unclassified MDS. All patients
received a standard myeloablative conditioning regi-
men. The same dataset has been used to evaluate
another matching algorithm, HLA Matchmaker [5].
Patients who received conditioning regimens of
lower intensity, those who underwent second or subse-
quent HCT, or surviving patients who did not provide
signed informed consent to allow analysis of their
clinical data orHLA typing of storedNMDPResearch
Repository samples were excluded. All surviving
recipients included in this analysis were contacted
retrospectively and provided informed consent for par-
ticipation in the NMDP research program. To adjust
for the potential bias introduced by exclusion of non-
consenting surviving patients, a modeling process ran-
domly excluded the same percentage of deceased
patients using a biased coin randomization, with exclu-
sion probabilities based on characteristics associated
with not providing consent for use of the data in
survivors [1].
Evaluation of HLA Disparity
HLA class I mismatches were scored by the
HistoCheck Web-based tool [13] (http://www.histo
check.de/). Patients were divided into 4 quartiles for
analysis based on dissimilarity score (DSS): group 1,
DSS 1.04-2.84; group 2, .2.84-13.75; group 3,
.13.75-19.39; and group 4, .19.39-36.62. In
addition, all analyses included an evaluation of DSS
score as a continuous variable. All cases were matched
for HLA-DRB1 and -DQB1. HLA-DPB1 matching
was available for all cases, but was not considered in
the analysis.
Clinical Endpoints
The association between HistoCheck score and
outcomes was evaluated, with disease-free survival
(DFS) as the primary endpoint and acute GVHD
grade II-IV, chronic GVHD, treatment-related mor-
tality (TRM), relapse, OS, and neutrophil engraftment
as secondary endpoints. DFS was defined as relapse or
death from any cause, with patients who were alive and
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follow-up. The incidence of grade II-IV acute
GVHD was determined during the first 100 days
post-HCT and defined according to the Glucksberg
scale [16]. Chronic GVHD was defined according to
the Seattle criteria [17]. TRM was defined as death
during a continuous complete remission. Relapse was
defined as relapse of leukemia or recurrence of MDS.
OS considered death from any cause as the event,
and surviving patients were censored at the date of
last contact. Neutrophil engraftment was defined as
achievement of an absolute neutrophil count .500
cells/mL for 3 consecutive measurements. Events
were summarized by the cumulative incidence esti-
mate, with death as the competing risk.
Statistical Analysis
To compare pretransplantation characteristics
for discrete factors, the number of cases and their
respective percentages were calculated, and the c2
test was applied to compare the HistoCheck-defined
HLA-MM groups. For continuous factors, the
medians and ranges were calculated, and the Kruskal-
Wallis test was used to analyze differences among the
HistoCheck quartile groups. Probabilities of DFS
were calculated using the Kaplan-Meier estimator.
Estimated cumulative incidence was used to describe
the probabilities for events with competing risks, in-
cluding engraftment, GVHD, relapse, and TRM. Sur-
vival curves were compared using the log-rank test.
The HistoCheck quartile groups were compared
by multivariate analyses using the Cox proportional
hazards model. Models were fit to determine
which risk factors were related to a given outcome.
All variables were tested for affirmation of the
proportional hazards assumption. Neutrophil recov-
ery at day 28 was modeled using a logistic regression
approach. Subset analyses were conducted by disease
and disease stage. Because of multiple comparisons,
a P value \.01 was used to determine statistical
significance.RESULTS
The characteristics of the study patients and their
HLA mismatches are summarized in Table 1. Patients
were grouped into quartiles based on the DSS received
for their specific HLA class I mismatch. Analysis of the
specificHLAmismatches found in each quartile corre-
lated with the type of mismatch found in each
category: DSS 1.04-2.84 (allele MM), DSS .2.84-
13.75 (allele and antigen MM), DSS .13.75-19.39
(antigen MM), and DSS .19.39-36.62 (antigen
MM). Table 1 shows the distribution of mismatches
at HLA-A, HLA-B, and HLA-C loci. The disease
stage distribution was significantly different (P 5 .04)across the quartiles, with patients in the highest DSS
quartile exhibiting more intermediate and advanced
disease than the other quartiles. No other characteris-
tics differed significantly among the quartile groups.
Although donors and recipients were all matched at
the HLA-DRB1 and -DQB1 loci, the majority were
HLA-DPB1 MM. The distribution of HLA-DPB1
mismatching did not differ across the quartile groups,
with 83%, 87%, 88%, and 88% mismatching for
groups 1-4, respectively (P 5 .47).
Graft-versus-Host Disease
Univariate analysis showed no difference in the
probabilities of grades II-IV acute GVHD at 100 days
among the 4 DSS groups, with 51%, 51%, 56%, and
51% for groups 1-4, respectively (P 5 .75) (Table 2
and Figure 1A). ChronicGVHD rates at 1 year also did
not differ among the DSS groups, with 39%, 34%,
35%, and 38% for groups 1-4, respectively (P 5 .70).
Multivariate analysis found significant associations
with grade II-IV acute GVHD and patient age, graft
type, and GVHD prophylaxis. After adjusting for
the significant covariates, no associations were found
with the DSS groups (overall P 5 .78) or with
DSS as a continuous variable (P 5 .50) (Table 3).
Chronic GVHD was significantly associated with
donor–recipient sex match, graft type, and GVHD
prophylaxis. After adjusting for significant covariates,
no associations were found with the DSS groups (over-
all P 5 .61) or with DSS as a continuous variable
(P 5 .89) (Table 3).
TRM
Univariate analysis found no differences in the
probability of TRM among the DSS groups at 1 year
(P 5 .48), 3 years (P 5 .54), or 5 years (P 5 .59)
(Table 2 and Figure 1B). The probabilities of TRM
at 1 year were 41%, 49%, 44%, and 45% for groups
1-4, respectively. Multivariate analysis revealed signif-
icant associations between TRM and cytomegalovirus
(CMV) match, Karnofsky score, recipient age, and
year of HCT. After adjusting for the significant cova-
riates, no associations were found between TRM and
DSS group (P 5 .29) or with DSS as a continuous
variable (P 5 .58) (Table 3).
Relapse
Univariate analysis revealed no differences in the
probability of relapse among the DSS groups at 1
year (P 5 .53), 3 years (P 5 .25), or 5 years (P 5 .44)
(Table 2 and Figure 1C). The probabilities of relapse
at 1 year were 14%, 16%, 14%, and 19% for groups
1-4, respectively. Multivariate analysis found signifi-
cant associations between relapse and disease status.
After adjusting for the significant covariate, no associ-
ations were found between relapse and DSS group
Table 1. Characteristics of Patients by Histocheck (DSS) Score Quartile of Mismatched Cases (7/8 HLA Class I Mismatches)
Variable
DSS Quartile
P Value*1.04-2.84 >2.84-13.75 >13.75-19.39 >19.39-36.62
Number of patients 187 189 182 186
Number of centers 62 69 55 66
Matching of loci, n (%)† <.001
HLA-A allele mismatch 49 (26) 49 (26) 0 0
HLA-A antigen mismatch 0 38 (20) 32 (18) 74 (40)
HLA-B allele mismatch 63 (34) 22 (12) 0 0
HLA-B antigen mismatch 0 4 (2) 2 (1) 6 (3)
HLA-C allele mismatch 75 (40) 5 (3) 0 0
HLA-C antigen mismatch 0 71 (37) 148 (81) 106 (57)
Age, years, median (range) 33 (<1-60) 32 (<1-60) 32 (<1-65) 30 (1-59) .42
Age at HCT, years, n (%) .22
#10 19 (10) 26 (14) 16 (9) 27 (15)
10-19 33 (18) 19 (10) 30 (17) 38 (20)
20-29 27 (14) 40 (21) 35 (19) 27 (15)
30-39 44 (24) 35 (18) 39 (21) 36 (19)
40-49 43 (23) 51 (27) 47 (26) 37 (20)
50 and older 21 (11) 18 (10) 15 (8) 21 (11)
Male sex, n (%) 93 (50) 98 (52) 107 (59) 99 (53) .34
Karnofsky score $90 before treatment, n (%) 124 (66) 143 (76) 130 (71) 137 (74) .12
Disease at transplantation, n (%) .10
Acute myelogenous leukemia 57 (31) 52 (28) 49 (27) 66 (35)
Acute lymphoblastic leukemia 47 (25) 49 (26) 48 (26) 55 (30)
Chronic myelogenous leukemia 73 (39) 74 (39) 64 (35) 48 (26)
Myelodysplastic syndrome 10 (5) 14 (7) 21 (12) 17 (9)
Disease status at HCT, n (%) .04
Early 71 (38) 84 (44) 72 (39) 58 (31)
Intermediate 89 (48) 67 (35) 74 (41) 76 (41)
Advanced 27 (14) 37 (20) 36 (20) 51 (27)
Other 0 1 (1) 0 1 (1)
Graft type, n (%) .008
Bone marrow 164 (88) 183 (97) 169 (93) 167 (90)
Peripheral blood 23 (12) 6 (3) 13 (7) 19 (10)
Conditioning regimen .71
Traditional myeloablative 180 (96) 185 (98) 176 (97) 182 (98)
Nontraditional ablative 7 (4) 4 (2) 6 (3) 4 (2)
Donor/recipient sex match, n (%) .26
Male/male 64 (34) 66 (35) 63 (35) 53 (28)
Male/female 51 (27) 47 (25) 45 (25) 44 (24)
Female/male 29 (16) 32 (17) 44 (24) 46 (25)
Female/female 43 (23) 44 (23) 30 (16) 43 (23)
GVHD prophylaxis, n (%) .20
Tacrolimus + (MTX or MMF or steroids) ± other 35 (19) 34 (18) 31 (17) 38 (20)
Tacrolimus ± other 2 (1) 0 1 (<1) 1 (<1)
CsA + MTX ± other 114 (61) 109 (58) 98 (54) 87 (47)
CsA ± MMF ± steroids ± other (no MTX) 2 (1) 7 (4) 6 (3) 3 (2)
MMF ± other 1 (<1) 0 0 0
MTX ± other (no CsA) 0 1 (<1) 2 (1) 0
T cell depletion 33 (18) 38 (20) 43 (24) 56 (30)
Other 0 0 1 (<1) 1 (<1)
Donor/recipient CMV match, n (%) .84
Negative/negative 62 (33) 58 (31) 59 (32) 73 (39)
Negative/positive 56 (30) 56 (30) 49 (27) 46 (25)
Positive/negative 30 (16) 35 (18) 28 (15) 32 (17)
Positive/positive 37 (20) 37 (19) 41 (23) 31 (17)
Unknown 2 (1) 3 (2) 5 (3) 4 (2)
Donor age, median (range), years 36 (19-57) 36 (19-54) 36 (19-59) 35 (19-59) .74
Donor age, years, n (%) .65
18-29 45 (24) 56 (30) 47 (26) 50 (27)
30-39 69 (37) 63 (33) 70 (38) 74 (40)
40-49 57 (30) 58 (31) 45 (25) 47 (25)
50 and older 16 (9) 12 (6) 20 (11) 15 (8)
Year of HCT, n (%) .06
1988 1 (<1) 1 (<1) 0 0
1989 1 (<1) 2 (1) 2 (1) 2 (1)
1990 3 (2) 2 (1) 2 (1) 6 (3)
1991 6 (3) 1 (<1) 5 (3) 8 (4)
1992 3 (2) 15 (8) 12 (7) 9 (5)
1993 9 (5) 6 (3) 10 (5) 9 (5)
1994 10 (5) 12 (6) 16 (9) 14 (7)
(Continued )
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Table 1. (Continued )
Variable
DSS Quartile
P Value*1.04-2.84 >2.84-13.75 >13.75-19.39 >19.39-36.62
1995 16 (9) 16 (8) 22 (12) 9 (5)
1996 12 (6) 15 (8) 13 (7) 16 (9)
1997 21 (11) 13 (7) 11 (6) 11 (6)
1998 15 (8) 20 (11) 15 (8) 11 (6)
1999 19 (10) 38 (20) 18 (10) 18 (10)
2000 24 (13) 17 (9) 18 (10) 19 (10)
2001 30 (16) 19 (10) 18 (10) 29 (16)
2002 11 (6) 11 (6) 15 (8) 19 (10)
2003 6 (3) 1 (<1) 5 (3) 6 (3)
Follow-up of survivors, months, median (range) 61 (6-191) 60 (7-179) 74 (24-184) 50 (12-175) .36
CsA indicates cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate.
*P values are derived using the c2 test for descriptive variables, the Kruskal-Wallis test for continuous variables, and the log-rank test for median follow-
up of survivors.
†Antigen mismatches were defined as mismatches differing in the first digits of the allele name (eg, A*02 versus A*68). Allele mismatches were defined as
mismatches differing in the third and fourth digits of the allele name (ie, digits after the first colon, eg, A*02:01 versus A*02:05).
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(P 5 .34) (Table 3).OS
Univariate analysis revealed no differences in the
probability of OS among the DSS groups at 1 year
(P 5 .50), 3 years (P 5 .31), or 5 years (P 5 .26)
(Table 2 and Figure 1D). The probabilities of OS at
1 year were 47%, 41%, 46%, and 41% for groups
1-4, respectively. Multivariate analysis showed signifi-
cant associations between OS and donor–recipient
CMVmatch, disease status, Karnofsky score, recipient
age, and year of HCT. After adjusting for the signifi-
cant covariates, no association was found between
OS and DSS group (P5 .14) or with DSS as a contin-
uous variable (P 5 .57) (Table 3).DFS
Univariate analysis revealed no differences in the
probability of relapse among the DSS groups at 1Table 2. Univariate Probabilities of Clinical Outcomes by Histoche
Outcome Time Point
Group 1,
DSS 1.04-2.84
Grou
DSS >2.8
Acute GVHD grade II-IV 100 days 51 (44-59) 51 (44
Chronic GVHD 1 year 39 (32-47) 34 (27
TRM 1 year 41 (34-48) 49 (42
3 years 46 (39-53) 51 (44
5 years 48 (41-56) 54 (47
Relapse 1 year 14 (10-20) 16 (11
3 years 18 (13-24) 21 (16
5 years 19 (14-25) 21 (16
OS 1 year 47 (40-54) 41 (34
3 years 38 (31-45) 32 (25
5 years 35 (28-43) 28 (22
DFS 1 year 45 (38-52) 35 (28
3 years 35 (29-43) 27 (21
5 years 33 (26-40) 25 (19
Neutrophil engraftment 28 days 92 (88-95) 90 (86
*P values are pointwise.year (P 5 .16), 3 years (P 5 0.21), or 5 years (P 5 .28)
(Table 2). The probabilities of relapse at 1 year were
45%, 35%, 42%, and 36% for groups 1-4, respectively.
Multivariate analysis found significant associations
between relapse and disease status. After adjusting for
the significant covariate, no association was found be-
tween relapse and DSS group (P 5 .06) or with DSS
as a continuous variable (P 5 .45) (Table 3).
Neutrophil Engraftment
Univariate analysis found no differences in the
probability of neutrophil engraftment among the
DSS groups at day 28 (P5 .09) (Table 2). The proba-
bilities of neutrophil engraftment at day 28 were 92%,
90%, 87%, and 85% for groups 1-4, respectively.Mul-
tivariate analysis revealed significant associations be-
tween neutrophil engraftment and year of HCT.
After adjusting for the significant covariate, no associ-
ations were found between relapse and DSS group
(P 5 .13) or with DSS as a continuous variable
(P 5 .03) (Table 3).ck (DSS) Score Quartiles of Mismatched Cases
Percent Probability (95% CI)
P Value*
p 2,
4-13.75
Group 3,
DSS >13.75-19.39
Group 4,
DSS. >13.39-36.62
-58) 56 (49-63) 51 (44-58) .75
-42) 35 (28-42) 38 (31-46) .70
-56) 44 (37-52) 45 (38-52) .48
-58) 54 (46-61) 49 (42-57) .54
-61) 55 (48-62) 52 (44-59) .59
-22) 14 (9-19) 19 (14-25) .53
-27) 17 (12-22) 25 (19-31) .25
-27) 18 (13-24) 25 (19-31) .44
-48) 46 (39-53) 41 (34-49) .50
-39) 33 (27-40) 29 (23-36) .31
-35) 31 (24-38) 26 (19-33) .26
-42) 42 (35-49) 36 (29-43) .16
-34) 30 (23-37) 26 (20-33) .21
-31) 27 (21-34) 24 (17-31) .28
-94) 87 (81-91) 85 (79-89) .09
Figure 1. Univariate analyses of outcomes by patient quartiles, based on the HistoCheck DSS of HLA class I mismatches. (A) Grade II-IV acute GVHD.
(B) TRM at 5 years. (C) Relapse at 5 years. (D) OS at 5 years.
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Previous studies suggested differing effects of
HLA matching based on disease and disease status
[1,18]. Disease and disease status subset multivariate
models were evaluated to assess the associations
between DSS score and all outcomes. Significant
associations were noted between engraftment rates at
day 28 and increasing DSS scores in early-stage disease
(P5 .0003). In addition, higher DSS scores were asso-
ciated with TRM, DFS, and OS in the MDS popula-
tion. However, the MDS population was quite small
(n 5 10-21), which limits confidence in the relevance
of this association.Table 3. Multivariate Analysis of Clinical Outcomes by HistoChe
Variable
Outcome
Group 1,
DSS 1.04-2.84*
Group 2,
DSS >2.84-13.75,
G
DSS
RR (95% CI) RR
Acute GVHD grade II-IV 1.00 1.06 (0.79-1.41) 1.05
Chronic GVHD 1.00 0.86 (0.61-1.21) 0.82
TRM 1.00 1.22 (0.91-1.63) 1.13
Relapse 1.00 1.47 (0.93-2.32) 0.99
OS 1.00 1.25 (0.98-1.61) 1.07
DFS 1.00 1.30 (1.01-1.66) 1.11
Neutrophil engraftment† 1.00 0.85 (0.41-1.75) 0.63
CI indicates confidence interval; RR, relative risk.
*Reference group.
†Data reported as odds ratio in favor of engraftment.DISCUSSION
The goal of this study was to test the hypothesis
that the HistoCheck scoring system, based on the
functional similarity of amino acids and their position
within the HLA molecule (ie, DSS score), could pre-
dict the outcomes of unrelated HCT using 7/8 class
I MM donors. The results of this study of 744 single
allele- or antigen-MM transplant recipients confirm
and extend the results of a study of 35 patients by
Shaw et al. [14], as well as an analysis of another regis-
try by Askar et al. [15]. The patients were divided into
quartiles based on their DSS scores, and tests to detectck DSS Score Quartile Groups and Treated as a Continuous
roup 3,
>13.75-19.39,
Group 4,
DSS >19.39-36.62,
Overall
P Value
DSS Continuous
P Value(95% CI) RR (95% CI)
(0.79-1.39) 1.16 (0.88-1.54) .78 .50
(0.59-1.14) 0.97 (0.69-1.37) .61 .89
(0.84-1.51) 1.32 (0.98-1.77) .29 .58
(0.61-1.60) 1.44 (0.93-2.26) .14 .34
(0.83-1.38) 1.28 (1.00-1.64) .14 .57
(0.86-1.42) 1.35 (1.05-1.73) .06 .45
(0.32-1.25) 0.48 (0.25-0.95) .13 .03
Biol Blood Marrow Transplant 18:739-746, 2012 745Scoring HLA Mismatchesdifferences among the quartiles were performed. The
overall observation of equality among the quartiles
suggests that the HistoCheck scoring system for
HLA class I mismatches is not predictive of HCT out-
comes as measured by survival, GVHD, relapse, or en-
graftment. We did not evaluate the HistoCheck
scoring system for HLA class II mismatches in this
study; however, a recent study found that mean DSS
scores did not differ significantly, and DSS distribu-
tions overlapped among the high- and low-risk allele
combinations considered responsible for severe acute
GVHD within HLA-DRB1 and -DPB1 loci [15].
Taken together, the results of our analysis and previ-
ous studies do not support the selection of unrelated
donors using the HistoCheck scoring system to
improve clinical outcomes.
There were some significant observations. Higher
DSS scoreswere associatedwith decreased engraftment
in early-stage disease (P5 .0003), but not in other dis-
ease stages. Anti-HLA antibodies in the recipient are
associated with higher rates of graft failure and lower
engraftment levels in HLA-MM unrelated donor
HCT [19]. Higher DSS scores were correlated with
more antigen-level mismatches (Table 1), which could
serve as targets for anti-HLA antibodies; however, the
presence of anti-HLA antibodies was not evaluable
in the dataset. In disease subset analyses, DSS score
was associatedwithTRM,DFS, andOS inMDS.How-
ever, the MDS subgroups were very small (n5 10-21),
diminishing confidence in these associations.
The HistoCheck algorithm has several limitations
that likely limit its ability to predict outcomes. In gen-
eral, the algorithm may not adequately reflect the
biological complexity inherent in the HLA/peptide/
T cell receptor (TCR) complex. The Risler amino
acid substitution score might not represent functional
similarities of amino acids with regard to peptide and
TCR binding. The algorithm’s adjustments for impact
on peptide and/or TCR binding may be too simplistic.
Its structural considerations based on crystallographic
data of a single allelic product, A*02:01, might not be
readily extrapolated to other allelic products, particu-
larly products of loci other than HLA-A. The influ-
ence of molecular interaction among amino acids is
not considered, and the differential binding of pep-
tides, particularly in the case of minor antigens, may
alter matching based on similarity. The algorithm
scoring strongly correlated with allele and antigen
mismatching (Table 1); however, previous studies
have found that both allele and antigen mismatches
can be detrimental to HCT outcomes [1]. It will be
challenging to develop an algorithm capable of pre-
dicting the impact of HLA allelic variation on the
strength of the allorecognition response.
A major hurdle to overcome in developing an
evidence-based scoring system for HLA disparities is
HLA diversity. This was recently demonstrated byan NMDP study of HLA-A disparities revealing 190
different mismatch combinations in 4226 donor–
recipient pairs and demonstrating that 51% of these
mismatches were observed in only 1 pair [20]. Because
the most frequent HLA-A mismatches in the HLA-B,
-C, and -DRB1, matched pairs were found only 2-6
times per 1000 patients undergoing HCT in the
United States, it is not feasible to directly determine
associations between a particular isolated HLA-A
disparity and transplantation outcomes in patients
undergoing HCT in the United States.
In contrast, a study of 5210 Japanese donor–
recipient pairs showed a high incidence of recurring
HLA-A disparities [9]. In that study, a single HLA
disparity was observed in 269 pairs and several HLA
disparities were observed in more than 40 pairs. Three
of these HLA-A disparities were associated with acute
GVHD, but only one direction of each disparity
reached statistical significance. This observation could
provide important insight into factors related to T cell
selection and/or recognition that might modulate
allogenicity. Although homogeneous populations,
such as the one in the Japanese study, can provide suf-
ficient numbers of a particular mismatch for isolated
study, the observations might not be applicable to
other populations, because other factors (eg, genetic
differences, environmental exposures) could alter the
alloreactive response. Furthermore, the particular re-
curring HLA disparities observed in the Japanese pop-
ulation often were not observed in other populations
that have been studied [8]. The challenge intensifies
if the investigation is reduced to an amino acid level,
because the context of each amino acid difference
likely will influence allorecognition [20].
The complexity generated by extensive HLA di-
versity, genetic variation, and other transplantation
factors (eg, disease and stage of disease, recipient
age) creates a daunting challenge for developing an
evidence-based scoring system for HLA disparities.
Until this challenge can be resolved, it is important
to exercise great caution in using untested algorithms
to guide donor selection. It is likely that very complex
models will be needed to meet this challenge.ACKNOWLEDGMENTS
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